Innovassynth

What Innovassynth does

Innovassynth Technologies (India) Ltd. is a publicly listed (BSE ticker: IIL) custom development and manufacturing organization (CDMO) headquartered in Pune, India, with a 60+ acre manufacturing complex in Khopoli, Maharashtra. The company operates two integrated business verticals: Life Sciences (nucleosides, phosphoramidites, GalNAc derivatives, ADC linkers, bio-buffers, and pharmaceutical intermediates) and Specialty Chemicals (organometallics including zirconium-based compounds, ZN catalysts and donors, ALD/CVD precursors for semiconductors, flavors & fragrance intermediates, and agro intermediates). Its stated core competency is nucleic acid chemistry, with claims to be the pioneer in commercial-scale nucleoside production from India and to support oligonucleotide drug programs from preclinical through clinical phase.

The company operates B2B across at least seven end-markets — pharma/biopharma, biotech and oligo manufacturers, petrochemicals, polymers, semiconductors, flavors & fragrances, and agrochemicals — serving 100+ global customers through enterprise field sales, supplemented by an e-commerce storefront with bulk-quotation functionality. Manufacturing assets include 10+ production lines with 250+ KL total reaction capacity, specialized cryogenic reactors, and Hastelloy calcination equipment rated to 800°C; R&D spans a 24,000 sq. ft facility with 9 labs and 60 fume hoods, staffed by 100+ scientists (including 20+ PhDs) and 200+ technicians. The workforce is approximately 600+ in total. Certifications include ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, ISO 27001:2022, a consecutive EcoVadis Gold Rating (2025), and an SBTi commitment initiated March 2025.

The business model combines custom development and contract manufacturing services (process R&D, scale-up, technology transfer, regulatory support, IP-protected engagements) with the sale of catalog specialty chemical products through direct sales and e-commerce. Pricing is quote-based with multi-year contract cadence and is not publicly disclosed. Q3 FY2025-26 (quarter ended December 2025) reported standalone sales of Rs 21.97 crore, down 55.98% YoY, with a swing to a Rs 7.80 crore net loss from a Rs 9.19 crore prior-year profit. A Rs 69.65 crore rights issue is scheduled for April 2026 to raise capital from existing shareholders.

Name

Innovassynth

Legal name

Innovassynth Technologies (India) Ltd.

Website

https://innovassynth.com

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Short description

Innovassynth is an India-based CDMO specializing in nucleic acid chemistry and specialty chemicals, providing custom development and commercial-scale manufacturing of nucleosides, phosphoramidites, organometallics, and pharmaceutical intermediates to global pharma, biotech, and specialty chemical customers.

Ownership category

akta.pro rank

Product category

Specialty Chemicals & CDMO Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAGABAA

Small-Molecule API & Intermediates CDMO

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

SECONDARYHLAGABAG

Drug Substance–Drug Product Integrated CDMO

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

SECONDARYHLAGABAB

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

• Custom chemical manufacturing
• Nucleoside synthesis
• Specialty chemicals
• CDMO services
• Organometallic compounds

Headquarters

HQ city

Khopoli

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Custom Development and Manufacturing (CDMO) Services: End-to-end custom development and manufacturing services including process development, optimization, scale-up, and commercialization. Services include technology transfer, process adoption, and regulatory support.
2. Specialty Chemical Products: Sale of specialty chemical products including nucleosides, phosphoramidites, organometallics, and pharmaceutical intermediates. Products sold in bulk quantities through direct sales and e-commerce platform.
3. Contract Manufacturing: Toll manufacturing services for various chemical reactions with consistent quality as per national and international standards. Manufacturing on campaign basis with dedicated plants.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Innovassynth is a Custom Development & Manufacturing Organization (CDMO) that provides custom synthesis, contract research, and commercial-scale manufacturing of nucleosides and specialty chemicals. The company operates two business verticals: Life Sciences (nucleosides, phosphoramidites, GalNAc conjugates, ADC linkers, bio-buffers, pharma intermediates) and Specialty Chemicals (organometallics, catalysts, ALD/CVD precursors, polymer additives, semiconductor chemicals, flavors & fragrance intermediates, agro intermediates). Services include custom R&D, process optimization, scale-up, contract manufacturing, and fee-for-services engagements for global pharmaceutical, biotech, and specialty chemical customers.

Product overview

Innovassynth operates as a unified Custom Development & Manufacturing Organization (CDMO) offering two integrated business verticals: Life Sciences - Nucleosides and Specialty Chemicals. The Life Sciences Nucleosides portfolio encompasses phosphoramidites, protected nucleosides, GalNAc delivery platforms, ADC linkers, pharma intermediates, reagents, and bio-buffers for pharmaceutical, biopharma, drug discovery, and oligo-manufacturing companies. The Specialty Chemicals vertical covers organometallics (pre-catalysts for metallocene, ZN catalysts, donors & ligands), polymers additives, ALD/CVD precursors for semiconductors, flavors & fragrance compounds, and agro intermediates. The company provides end-to-end CDMO services including custom research & development, contract manufacturing, and fee-for-services, supporting customers from concept through commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

• Lifesciences Nucleosides A comprehensive portfolio of nucleoside products including Phosphoramidites, protected Nucleosides, Reagents, Bio-buffers, GalNAc derivatives, and ADC Linkers offered to pharmaceutical, biopharma, drug discovery, and oligo-manufacturing companies globally, including specialty RNA Phosphoramidite products manufactured at commercial scale.
• Specialty Chemicals A broad portfolio of specialty chemicals including Organometallics (pre-catalysts for metallocene, ZN catalysts, donors & ligands), Polymers additives, ALD/CVD precursors, Semiconductor Chemicals, Flavours & Fragrance compounds, and Agro Intermediates serving petrochemicals, polymers, semiconductors, and flavors & fragrance industries.
• CDMO (Custom Development & Manufacturing) Services Custom Development & Manufacturing services offering comprehensive support from process development and optimization through scale-up to commercialization, including Custom Research & Development, Contract Manufacturing, and Full Time Equivalent/Fee-for-Services options for life sciences and specialty chemical industries.

Quantifiable outcome

• Commercial-scale nucleoside production capability from India
• +2 more outcomes

Named customers9 records

Segments7 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Wuxi AppTec: One of the largest global CRO/CDMOs with extensive nucleic acid chemistry and oligonucleotide CDMO capabilities. Directly comparable to Innovassynth's life-sciences nucleosides vertical but operating at vastly greater scale across the full small- and large-molecule spectrum.
• Eurofins CDMO (Eurofins Genomics/Biomnis): European-headquartered life-sciences CDMO with nucleic acid chemistry and oligonucleotide synthesis offerings. Overlaps with Innovassynth's phosphoramidite, nucleoside, and custom oligo intermediate capabilities for pharma/biotech customers.
• Syngene International: Indian publicly-listed CRO/CDMO offering custom research, development, and manufacturing services to global pharma. Comparable in B2B custom-synthesis model, India footprint, and breadth of services from concept to commercialization.
• Piramal Pharma Solutions: Large India-based CDMO offering integrated custom development and manufacturing across small-molecule APIs, including nucleic-acid and oligonucleotide intermediates. Comparable commercial-scale capabilities and global B2B enterprise sales model.

Direct peers

• Sai Life Sciences: India-based CDMO providing contract development and manufacturing services across small molecules and intermediates for global pharma. Directly comparable India-based custom synthesis CDMO with overlapping customer segment and chemistry platforms.
• Ajinomoto Bio-Pharma Services: CDMO specialized in oligonucleotide and nucleic acid API manufacturing (formerly Ajinomoto Bio-Pharma). Competes head-to-head with Innovassynth's nucleoside/phosphoramidite offering for the same oligonucleotide innovator customer base.
• ChemPartner (Shanghai ChemPartner): Asia-based contract research and CDMO with discovery chemistry, process R&D, and custom manufacturing capabilities for life sciences customers. Overlaps with Innovassynth's end-to-end custom development positioning and pharma/biotech customer base.
• Asymchem Laboratories: China-based CDMO offering custom development and manufacturing of small-molecule APIs, intermediates, and specialty chemicals — including nucleic acid precursors. Comparable end-to-end CDMO model and global pharma customer base.
• Anthem Biosciences: India-based CDMO providing custom synthesis and contract manufacturing for pharma and biotech, including complex intermediates. Directly comparable in product mix, customer type, and custom-synthesis business model.
• Aurigene Pharmaceutical Services: India-based CDMO offering custom synthesis, process R&D, and oligonucleotide-related chemistry. Closest Indian peer to Innovassynth given shared geography, customer segment (global pharma/biotech), and custom synthesis value proposition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@Innovassynth
• LinkedInlinkedin.com/company/innovassynth-technologies-2001

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innovassynth